Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial
- 2020-01-30
- RCT · n = 330
- Nutrients 12(2)
- C. Martoni
- S. Srivastava
- G. Leyer
- PubMed: 32019158
- DOI: 10.3390/nu12020363
- High evidence
- Large Human Trial
Over the intervention period, APS-NRS was significantly improved in both probiotic groups vs. placebo in absolute terms (DDS-1: -2.59 ± 2.07, p = 0.001; UABla-12: -1.56 ± 1.83, p = 0.001) and in percentage of significant responders (DDS-1: 52.3%, p < 0.001); UABla-12 (28.2%, p = 0.031).
- Effect
- Beneficial
- Effect size
- Large
- Significant
- Yes